CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40. Wang R, Graham S, Sun N, McCarthy D, et al. PLoS One 2020;15:e0228221.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang R, Graham S, Sun N, McCarthy D, et al. CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40. PLoS One 2020;15:e0228221.
PMID: 32155151